Contraindicated (1)bortezomib will raise the degree or influence of mavacamten by impacting hepatic enzyme CYP2C19 metabolism. Contraindicated. Solid or moderate CYP2C19 inhibitors may increase mavacamten systemic publicity, leading to coronary heart failure due to systolic dysfunction.Lower disorder action has been described and examined, and esse… Read More